{"id":4844,"date":"2025-10-02T12:50:49","date_gmt":"2025-10-02T12:50:49","guid":{"rendered":"https:\/\/thegloss.online\/?p=4844"},"modified":"2025-10-02T12:50:49","modified_gmt":"2025-10-02T12:50:49","slug":"whats-in-a-name-why-this-ai-startup-honours-aaron-swartz-in-its-mission-to-transform-drug-development","status":"publish","type":"post","link":"https:\/\/thegloss.online\/?p=4844","title":{"rendered":"What\u2019s in a Name: Why this AI startup honours Aaron Swartz in its mission to transform drug development"},"content":{"rendered":"

<\/p>\n

\n

Currently, the process of developing new drugs is frustratingly slow, costly, and risky.<\/p>\n

It usually takes more than 10 years and over $2.3B to bring a successful drug to market, and in fact, 90 per cent of drug candidates fail before they get to patients.<\/p>\n

Many of these failures could have been avoided if we had better data to address safety and effectiveness concerns.<\/p>\n

Additionally, a substantial amount of valuable biomedical information (nearly 90 per cent) is not utilised in critical decision-making processes, leaving experts with incomplete information.<\/p>\n

As a result, this means that many potentially life-saving treatments never make it to the people who need them.<\/p>\n

Here\u2019s where ArcaScience<\/a> comes in!<\/p>\n\n

Contentlockr<\/p>\n\n

Addressing the bottleneck in drug development<\/h2>\n

Founded to address this critical bottleneck in drug development, ArcaScience has pioneered the development of AI to radically improve benefit-risk assessments for pharmaceuticals & regulators, empowering both clinical teams and patients.<\/p>\n

The company does this by using AI to transform unstructured biomedical data into benefit-risk predictions.<\/p>\n

This helps pharmaceutical companies better evaluate drug candidates.<\/p>\n

In this edition of \u201cWhat\u2019s in a Name,\u201d we spoke to Romain Clement, founder of ArcaScience, to learn more about the inspiration behind the name and how the process reflects the company\u2019s broader mission and vision.<\/p>\n

Inspired by Aaron Swartz<\/h2>\n

Romain explains that their choice was never random. It carried a personal connection and a nod to someone who shaped their worldview.<\/p>\n

\u00a0\u201cWe chose \u201cArca\u201d in tribute to Aaron Swartz\u2014\u201cthe Internet\u2019s Own Boy\u201d\u2014whose commitment to open knowledge shaped a generation. In Latin, arca<\/em> means an ark or chest: a vessel for what must be preserved and put to use. The more legendary echo is the Ark of the Covenant and Aaron, its first guardian, a symbol of stewardship and integrity,\u201d says<\/p>\n

He believes that it reflects their ethos \u2014 to safeguard the world\u2019s biomedical evidence and transform it into actionable, patient-centred insights, enabling drug developers to assess benefit-risk instantly and advance therapies responsibly.<\/p>\n

A name aligned with purpose<\/h2>\n

He believes the name goes beyond just identity. The name reflects their mission in healthcare and the role they want to play in drug development.<\/p>\n

\u201cIn a world where drug development is slow, risky, and often blind to emerging evidence, ArcaScience brings clarity. We decode the biomedical statistics, real-world evidence, and clinical trials into a living benefit-risk framework that helps pharma make faster, safer, and smarter decisions \u2014 for patients and for progress,\u201d he explains.<\/p>\n

\u201cWe stand at the intersection of open science and industrial impact. Where Aaron fought to free knowledge, Arca gives it purpose,\u201d he adds.<\/p>\n

Finding the name<\/h2>\n

Choosing a name from thousands of ideas usually takes time, involving meetings and jotting down lists. However, for Arca, the naming process was surprisingly straightforward.<\/p>\n

\u201cWhen it came to finding a name, it was obvious that we wanted to pay tribute to Aaron Swartz. From there, we found it easily,\u201d says Romain.<\/p>\n

Domain name and trademarking<\/h2>\n

For many startups, securing a domain and trademark can be complicated. For Arca, both decisions were quick and easy.<\/p>\n

Romain explains, \u201cIt wasn\u2019t important at all. We knew we wanted an .ai domain, which was extremely rare at that time.\u201d He adds, \u201cIt wasn\u2019t a problem for us since our chosen name, along with the .ai domain, was still available.\u201d<\/p>\n

Looking ahead<\/h2>\n

According to Romain, the name gives them flexibility for the future, and they have already considered options as they grow.<\/p>\n

\u201cYes, we have already discussed using the second part, which is now \u2018Science\u2019, as a market-specific approach. Our technology could apply to other domains, but we will remain focused on healthcare at least until we have realised our vision completely.\u201d<\/p>\n

Does the name matter?<\/h2>\n

While the name has a value, Romain emphasises that people, not branding, determine a company\u2019s success.<\/p>\n

\u201cNo, it\u2019s the people that are, were, and will be in the company, as a whole, that made, make and will make its success. The name is only a vessel for a vision that we all share and value,\u201d he concludes.\u00a0<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Currently, the process of developing new drugs is frustratingly slow, costly, and risky. It usually takes more than 10 years and over $2.3B to bring a successful drug to market, and in fact, 90 per cent of drug candidates fail before they get to patients. Many of these failures could have been avoided if we<\/p>\n","protected":false},"author":1,"featured_media":4845,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[24],"tags":[1369,1070,1219,1368,1371,1367,1370,1372,212],"class_list":{"0":"post-4844","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-whats-in","8":"tag-aaron","9":"tag-development","10":"tag-drug","11":"tag-honours","12":"tag-mission","13":"tag-startup","14":"tag-swartz","15":"tag-transform","16":"tag-whats"},"_links":{"self":[{"href":"https:\/\/thegloss.online\/index.php?rest_route=\/wp\/v2\/posts\/4844","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thegloss.online\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thegloss.online\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thegloss.online\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thegloss.online\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4844"}],"version-history":[{"count":0,"href":"https:\/\/thegloss.online\/index.php?rest_route=\/wp\/v2\/posts\/4844\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/thegloss.online\/index.php?rest_route=\/wp\/v2\/media\/4845"}],"wp:attachment":[{"href":"https:\/\/thegloss.online\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4844"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thegloss.online\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4844"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thegloss.online\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4844"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}